Industrializing Design, Development, and Manufacturing of Therapeutic Proteins - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industrializing Design, Development, and Manufacturing of Therapeutic Proteins
The authors discuss various approaches and related issues, including production of difficult-to express proteins using cell-free expression systems, scalability of protein expression, and site-specific chemical modifications.


Pharmaceutical Technology
Volume 35, pp. s8-s11

Combinatorial screening of proteins

The advancements in genomic research and increased numbers of sequenced genomes require expression systems that allow fast production of the proteins under investigation. Cell-free expression systems can provide a useful tool for rapid screening and analysis of protein function, which is important for protein-drug discovery and development. DNA molecules can be amplified, transcribed, and translated in microplate wells and the expressed protein can be assayed immediately (15). Recently, HTS in a cell-free wheat germ system led to the discovery of a novel malaria vaccine candidate (16). Finally, the linear scalability allows proteins identified in display-based selections and HTS to be immediately scaled for production of multiple gram quantities, thus avoiding the delays and challenges of conventional mammalian cell line development.

Currently, cell-based expression technologies exhibit several limitations with respect to protein production at all phases of the drug discovery and development pipeline. Rapid production of proteins with novel chemical modifications, such as ADCs, are particularly challenging. E. coli-based cell-free protein synthesis systems, however, provide robust, rapid,and scalable protein production. The E. coli-based OCFS system, in particular, allows rapid and multiplexed production of various difficult to express proteins and opens the unprecedented ability to explore therapeutics beyond the 20 amino acids that define today's proteins (17). The OCFS, combined with rational protein design and the focused use of libraries of nnAAs, allows for rapid exploration and identification of protein therapeutics, moving from the exploratory stage to clinical scale-up on an unprecedented, rapid timescale.

Conclusion

Growing demand for new and better biopharmaceuticals has led to sophisticated advances in protein synthesis that now allow for:

  • Rapid production of target proteins, including those that are difficult to express in cell-based expression systems
  • Straightforward scalability of protein expression from HTS to commercial levels
  • Combinatorial screening of many proteins to identify and optimize drug candidates
  • Introduction of site-specific chemical modifications, including nnAAs into proteins to improve pharmacological properties

These new approaches to protein expression will revolutionize the development of biopharmaceuticals, and open up the possibility to create drugs that were previously inaccessible, and even unimaginable until now.

Trevor Hallam* is chief scientific officer and Christopher Murray is vice-president of research, both at Sutro Biopharma, 310 Utah Ave, Suite 150, South San Francisco, CA 94080,
.

* To whom all correspondence should be addressed


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here